{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/PFE/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://creativecommons.org/publicdomain/zero/1.0/","generated_at":"2026-05-16T06:14:17.560Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8278,"canonical_name":"PFIZER INC","cik":"0000078003","uei":null,"lei":null,"duns":null,"ticker":"PFE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":24,"sec":4},"count":28,"timeline":[{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT05287126","excerpt":"[\"Ulcerative Colitis\"]","importance":45},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07497854","excerpt":"[\"Migraine With or Without Aura\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06215118","excerpt":"[\"Multiple Myeloma\"]","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07556549","excerpt":"[\"Non-Small Cell Lung Cancer ALK-positive\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Pfizer","title":"Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05156398","excerpt":"[\"Migraine\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers","security_title":"PHASE1","status":"TERMINATED","accession_number":"NCT06870487","excerpt":"The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns","importance":80},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Pfizer","title":"Consistency of Response With Rimegepant in Acute Treatment of Migraine","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06898047","excerpt":"[\"Migraine\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06551324","excerpt":"[\"Metastatic Castrate Resistant Prostate Cancer (mCRPC)\"]","importance":60},{"ts":"2026-05-01","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT05441215","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Pfizer","title":"To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults","security_title":"PHASE1,PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05805826","excerpt":"[\"Clostridoides Difficile Associated Disease\"]","importance":45},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — PFIZER INC — 2026-04-27","url_slug":"/sec/cik-0000078003/8-k/0000078003-26-000044","accession_number":"0000078003-26-000044","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"4","title":"4 — NORA JOHNSON SUZANNE M — 2026-04-27","url_slug":"/sec/cik-0001310264/4/0001225208-26-004662","accession_number":"0001225208-26-004662","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"4","title":"4 — Gottlieb Scott — 2026-04-27","url_slug":"/sec/cik-0001411359/4/0001225208-26-004663","accession_number":"0001225208-26-004663","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"4","title":"4 — Desmond-Hellmann Susan — 2026-04-27","url_slug":"/sec/cik-0001507911/4/0001225208-26-004658","accession_number":"0001225208-26-004658","importance":30},{"ts":"2026-04-20","kind":"clinical.trial","reporter":"Pfizer","title":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","security_title":"PHASE2,PHASE3","status":"RECRUITING","accession_number":"NCT07226999","excerpt":"[\"Small Cell Lung Cancer (SCLC)\"]","importance":60},{"ts":"2026-04-16","kind":"clinical.trial","reporter":"Pfizer","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT04606446","excerpt":"[\"Locally Advanced or Metastatic ER+ HER2- Breast Cancer\",\"Locally Advanced or Metastatic Castration-resistant Prostate Cancer\",\"Locally Advanced or Metastatic Non-small Cell Lung Cancer\"]","importance":45},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).","security_title":null,"status":"RECRUITING","accession_number":"NCT06297161","excerpt":"[\"Chronic Leukemia Myelogenous\"]","importance":25},{"ts":"2026-03-30","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis","security_title":null,"status":"RECRUITING","accession_number":"NCT06294925","excerpt":"[\"Colitis, Ulcerative\"]","importance":25},{"ts":"2026-03-23","kind":"clinical.trial","reporter":"Pfizer","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07489066","excerpt":"[\"Carcinoma\",\"Non-Small-Cell Lung\",\"Lung Cancer (NSCLC)\",\"Lung Neoplasms\",\"Carcinoma, Non-Small-Cell Lung (NSCLC)\",\"Lung Disease\",\"Non-Small Cell Lung Cancer\",\"Non-small Cell Lung Cancer, Non-squamous\",\"Non-small Cell Lung Cancer, Squamous\"]","importance":45},{"ts":"2026-03-20","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06994897","excerpt":"[\"Healthy\"]","importance":30},{"ts":"2026-03-13","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06704724","excerpt":"[\"Carcinoma, Pancreatic Ductal\",\"Colorectal Neoplasms\",\"Carcinoma, Non-Small-Cell Lung\"]","importance":30},{"ts":"2026-02-10","kind":"clinical.trial","reporter":"Pfizer","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05909397","excerpt":"[\"Breast Cancer\"]","importance":60},{"ts":"2026-01-09","kind":"clinical.trial","reporter":"Pfizer","title":"Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)","security_title":"PHASE1,PHASE2","status":"TERMINATED","accession_number":"NCT04585815","excerpt":"Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions","importance":80},{"ts":"2025-12-17","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease","security_title":"PHASE3","status":"TERMINATED","accession_number":"NCT05348915","excerpt":"Sponsor decision to terminate study based on results of parent study GBT2104-131.","importance":80},{"ts":"2025-12-11","kind":"clinical.trial","reporter":"Pfizer","title":"Monitoring Activity And Gait In Children","security_title":null,"status":"COMPLETED","accession_number":"NCT04823650","excerpt":"[\"Child, Preschool\",\"Child\",\"Adolescent\"]","importance":25},{"ts":"2025-12-05","kind":"clinical.trial","reporter":"Pfizer","title":"BESPONSA Injection 1 mg Special Investigation","security_title":null,"status":"COMPLETED","accession_number":"NCT05923112","excerpt":"[\"Acute Lymphocytic Leukemia\"]","importance":25},{"ts":"2025-11-25","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.","security_title":null,"status":"COMPLETED","accession_number":"NCT06085924","excerpt":"[\"COVID-19\"]","importance":25},{"ts":"2025-11-20","kind":"clinical.trial","reporter":"Pfizer","title":"A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","security_title":null,"status":"COMPLETED","accession_number":"NCT06321523","excerpt":"[\"Transthyretin Amyloid Cardiomyopathy\"]","importance":25}]}